A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
At a glance
- Drugs AZD 1208 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 16 May 2018 Results of dose-escalation part of two studies including this study published in the British Journal of Cancer.
- 20 Apr 2016 Pooled analysis of 2 studies, including 35 patients from this trial and 32 patients from another study [see CTP 700211022] were presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 18 Aug 2015 Trial focus is changed from AR TO TU as reported by ClinicalTrials.gov record